B-Cell Lymphomas Coverage from Every Angle

Roni Shouval, MD, PhD, on Clinical Implications of New Findings on TP53, Large B-Cell Lymphoma, and CAR T-Cell Therapy

Posted: Tuesday, February 1, 2022

Roni Shouval, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the clinical and potentially cost-saving implications of new data that show TP53 alterations may lead to an immunosuppressive tumor microenvironment and impaired apoptosis signaling, which could result in decreased CAR T-cell therapy efficacy for patients with large B-cell lymphoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.